Clinical Trial Update: A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, and immunogenicity of the live attenuated hRSV vaccine rBCG-N-hRSV; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infections

Drugs mentioned

• rBCG-N-hRSV

Snippet

Sponsor: Pontificia Universidad Catolica de Chile | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED | Results posted: 2020-12-11